Autoimmune Diseases  >>  otelixizumab (ChAglyCD3)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
otelixizumab (ChAglyCD3) / GSK
NCT00946257: Subcutaneous Administration of Otelixizumab to T1DM Patients

Completed
1
33
Europe
Otelixizumab
GlaxoSmithKline
Diabetes Mellitus, Type 1
08/11
06/13
NCT01077531: Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis

Terminated
1
12
Europe, RoW
Otelixizumab, Matching placebo
GlaxoSmithKline
Arthritis, Rheumatoid
03/13
03/13

Download Options